Background: The COINCIDE trial aims to evaluate the effectiveness and cost-effectiveness of a collaborative care intervention for depression in people with diabetes and/or coronary heart disease attending English general practices. Design: This update details changes to the cluster and patient recruitment strategy for the COINCIDE study. The original protocol was published in Trials (http://www.trialsjournal.com/content/pdf/1745-6215-13-139.pdf). Modifications were made to the recruitment targets in response to lower-than-expected patient recruitment at the first ten general practices recruited into the study. In order to boost patient numbers and retain statistical power, the number of general practices recruited was increased from 30 to 36. Follow-up period was shortened from 6 months to 4 months to ensure that patients recruited to the trial could be followed up by the end of the study. Results: Patient recruitment began on the 01/05/2012 and is planned to be completed by the 30/04/2013. Recruitment for general practices was completed on 31/10/2012, by which time the target of 36 practices had been recruited. The main trial results will be published in a peer-reviewed journal.
Update

Introduction
The Collaborative Interventions for Circulation and Depression (COINCIDE) trial aims to investigate the effectiveness and cost-effectiveness of a collaborative care intervention for depression for people with diabetes and/or coronary heart disease [1] . The study is a clusterrandomised controlled trial conducted in English general practices. General practices were randomised to either a collaborative care arm or a usual care arm. The primary outcome is change in depression severity, as measured on the symptoms checklist-90 (SCL-90).
Eligible patients will be listed on Quality and Outcomes Framework disease registers for diabetes and/or coronary heart disease at the participating general practices. Due to poor detection rates and under-referral for treatment for depression in primary care in the UK, consenting patients will be screened for depression by the trial team using the Patient Health Questionnaire-9 (PHQ-9) on two occasions, two weeks apart. Patients will be considered to be depressed if they return PHQ-9 scores ≥10 on both occasions. Patients will be excluded from the study if they have a current diagnosis of dementia, are currently receiving a psychosocial intervention for depression, or treatment for drug or alcohol dependence.
Study progress Patient and GP practice recruitment
General practice recruitment began on 3 January 2012. The patient recruitment phase of the trial began when the first patient was recruited into the study on 1 May 2012. The average number of patients recruited per practice was assessed after the first eleven practices had finished recruitment. The average number of patients for these practices was 10 (range 4 to 22), below the target figure of 15 per practice.
The Trial Steering Committee (TSC) met on 17/10/12 when strategies for enhancing recruitment into the trial were discussed. It was agreed that the most efficient method to improve patient recruitment was to increase the number of general practices in the trial and to reduce the follow-up period. Ethical and research governance approval (see Amendment 9 from the NRES Committee North West -Preston, REF 11/NW/0742) was therefore sought to revise the sample size. To ensure that we retained power to detect a difference in the main outcome measure (SCL-90) we increased the number of clusters from 30 to 36. If we recruit 10 patients per practice then we anticipate a final sample size of 360. With an average of 10 patients over 36 practices (18 control/18 intervention) the study will have 79.1% power to detect a moderate standardised effect size of 0.4 at the 5% level of significance, allowing for an intraclass correlation (ICC) of 0.06.
GP and patient recruitment ran concurrently until 31 October 2012, when the target of 36 general practices was achieved.
Follow-up
To take into account the additional time needed to recruit patients from six additional clusters, baseline patient recruitment was extended until 30 April 2013. Ethical and research governance approval (see Amendment 9 from the NRES Committee North West -Preston, REF 11/NW/0742) was granted to reduce the follow-up period from six to four months, owing to the need to complete all follow-up before the end-of-study date on 30 September 2013. Follow-up at four months post randomisation has been used in other depression trials in primary care and is the earliest time point that we might anticipate detecting a treatment effect [2] .
Discussion
Modifications to cluster and patient recruitment targets following feedback to the TSC have offered opportunities for this trial to retain adequate statistical power and deliver on all aims and objectives. This process underlines the importance of regular scrutiny of study progress by both the research and project management team and by independent monitors, such as a TSC [3] . Competing interests PC, CG, CJG, CK, IA, KR, AC, FJ, CD, CCG declare they have no competing interests. PB is a paid scientific consultant to the British Association of Counselling and Psychotherapy.
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